Navigation Links
Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
Date:5/7/2008

ifferences,

if any, in the rates of valvulopathy (as defined by the Food and Drug

Administration, or FDA) in patients treated with lorcaserin and in the

control group did not meet the ESMB's predetermined stopping criteria.

o Announced the initiation of a Phase 1 clinical trial of a second

generation oral niacin receptor agonist intended for the treatment of

atherosclerosis in partnership with Merck & Co., Inc.

o Entered into strategic agreements with Siegfried Ltd primarily related

to the manufacturing of lorcaserin for Arena's planned New Drug

Application submission to the FDA and for commercialization of

lorcaserin after regulatory marketing approval. The agreements include

the purchase of certain drug product manufacturing and packaging

facility assets, including fixtures, equipment, other personal property

and real estate assets, located in Zofingen, Switzerland.

o Reported positive Phase 1a clinical trial results of APD791, Arena's

oral, internally discovered drug candidate intended for the treatment of

arterial thrombosis, and initiated a Phase 1b clinical trial to further

evaluate this drug candidate.

o Announced that initial clinical trial results for APD668, an oral drug

candidate discovered by Arena and being investigated for the treatment

of type 2 diabetes in partnership with Ortho-McNeil Pharmaceutical,

Inc., suggest that the Glucose-Dependent Insulinotropic Receptor, or

GDIR, improves glucose control in patients with type 2 diabetes. Based

on the data from those studies, Ortho-McNeil put APD668 on hold and

advanced a potentially more potent Arena-discovered GDIR agonist into

preclinical development.

Scheduled Earnings Call

Arena will host both a conference call and webcast to discuss the first quarter 2008 financial results and to provide a corporat
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval application ... the use of Medtronic,s SynchroMed ® II implantable ... use with United Therapeutics, Remodulin ® (treprostinil) Injection ...
(Date:12/24/2014)... 24, 2014   BioLife Solutions , Inc. (NASDAQ: ... clinical grade hypothermic storage and cryopreservation freeze ... cells and tissues  ("BioLife" or the "Company"), today announced that ... May 4, 2015 (the "Annual Meeting"). Because the ...
(Date:12/24/2014)... Earlier this year in a June 24 international ... Stem Cell Technology Center, LLC ( ASCTC ) focused attention ... adult tissue stem cells. His title “Asymmetric Self-Renewal by ... Future,” embodied the essence of his message to congress participants. ...
(Date:12/24/2014)... 23, 2014 According to Ross Selinger, President ... of ITRA Global, the national office market continues to be ... This is evidenced by the third quarter’s surprising 3.9% GDP, ... Low energy costs have held inflation down and the Fed ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3
... MSEDMONTON, March 17 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: ... sclerosis (MS), today announced financial and operational results for ... demonstrated the ability to safely affect MS progression in ... of the Canadian/European trial (MAESTRO-01) in the second half ...
... LONDON and WASHINGTON, March 17 Gentag, Inc. (Gentag) ... VCG & Associates Inc. and Talisman Management Ltd. to ... of all or parts of its IP portfolio. ... pharmaceutical and medical diagnostic uses on a global or ...
... AMGN ) will present at the Cowen and ... at the Boston Marriott Copley Place, Boston, Mass., beginning at ... President of North American Commercial Operations, will present. Live audio ... can be accessed from Amgen,s Web site, www.amgen.com , ...
Cached Biology Technology:BioMS Medical Announces 2008 Year End Results 2BioMS Medical Announces 2008 Year End Results 3BioMS Medical Announces 2008 Year End Results 4BioMS Medical Announces 2008 Year End Results 5BioMS Medical Announces 2008 Year End Results 6BioMS Medical Announces 2008 Year End Results 7BioMS Medical Announces 2008 Year End Results 8BioMS Medical Announces 2008 Year End Results 9BioMS Medical Announces 2008 Year End Results 10BioMS Medical Announces 2008 Year End Results 11Gentag, Inc. Engages US and UK Firms to Explore Strategic Options 2
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ...
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research and Markets ... of the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is a technology ... measures the overall facial feature of a person such ...
(Date:12/11/2014)...  That blood pressure plays a role in human health has ... term for high blood pressure – was first described as ... that,s used in measuring blood pressure was invented in 1896. ... hypertension, its triggers and its effects. In fact, recent findings ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... Nov. 12, 2013 One of the most comprehensive ... today, demonstrating an unprecedented level of genetic variation that ... ovarian cancer. The study highlights potential new pathways for ... multiple disease sites may be required for effective targeted ...
... as clear as glass, or why bakers use sugar, even ... in the American Chemical Society,s (ACS,) latest Bytesize Science ... . "Everything that happens in the kitchen is science," ... of it, you,re going to have more power over your ...
... protein, they tend to eat a small amount at ... at dinner. New research presented today at The ... eating high protein sausage and egg-based breakfasts curbed hunger ... and syrup) or skipping breakfast, in 18-55-year-old women., ...
Cached Biology News:Clinical ovarian cancers display extensive genetic heterogeneity, study suggests multiple treatment 2Clinical ovarian cancers display extensive genetic heterogeneity, study suggests multiple treatment 3
... Product Mouse monoclonal [SPM278] to ... Small cell lung carcinoma N592 live cells ... with Human. Not yet tested in other ... of the major glycoproteins of basement membrane, ...
TLN2 Antibody...
Chicken polyclonal to Thaumatin 2 ( Abpromise for all tested applications). Antigen: Full length Thaumatin 2...
XIAP Antibody...
Biology Products: